High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina
Rheumatology International · 2026
DOI: 10.1007/s00296-026-06131-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Rheumatology International, 2026. Verfasst von Rodrigo Garcia-Salinas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Hospital Italiano de La Plata, Universidad Nacional de La Plata, 51 Street, 1725, 1900, La Plata, Buenos Aires Province, Argentina…. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antirheumatic Agents, Interleukin-23, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Interleukin-23 inhibitors (IL-23i) are effective in psoriatic arthritis (PsA) in randomized trials; however, real-world data from Latin America remain limited. We described baseline characteristics and treatment line at IL-23i initiation, physician-reported reasons for selecting IL-23 inhibition, and pragmatic effectiveness and persistence at 6 and 12 months in Argentina. Multicenter, observational, retrospective cohort study across seven Argentine sites. Adults with rheumatologist-diagnosed PsA initiating IL-23i (guselkumab or risankizumab) in routine care were included. Baseline demographics, disease duration, domains, key activity measures, prior advanced therapy lines, and physician-reported rationale were abstracted from records. Patients were assessed at ~ 6 and 12 months. Primary outcome was physician-recorded minimal disease activity (MDA); persistence was remaining on IL-23i. Analyses were descriptive, with no inferential/predictive analyses due to sample size. Fifty-five patients were included (48% female; age 56 ± 11 years). Mean PsA duration before IL-23i was 7.7 ± 5.8 years and psoriasis duration 19 ± 11 years. IL-23i was initiated as the 1st, 2nd, or ≥ 3rd advanced line in 26%, 34%, and 39%, respectively; prior TNF inhibitor exposure was 75% and IL-17 inhibitor exposure 25%. Domain involvement was frequent (peripheral 95%, skin 91%, nails 44%, enthesitis 43%, dactylitis 13%, axial 17%). Physicians selected IL-23i mainly for safety (73.9%) and expected skin efficacy (69.6%). MDA was achieved by 70% at 6 months (90% persistence) and 75% at 12 months (80% persistence). In Argentine routine care, IL-23 inhibition achieved high MDA rates with substantial 12-month persistence in complex, treatment-experienced PsA, supporting its pragmatic use in daily practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Unit, Hospital Italiano de La Plata, Universidad Nacional de La Plata, 51 Street, 1725, 1900, La Plata, Buenos Aires Province, Argentina. gsalinasrodrigo@gmail.com.
- Sanatorio Mendez, Ciudad de Buenos Aires, Argentina.
- Instituto CER, Quilmes, Argentina.
- CEMEC, Casilda, Santa Fe, Argentina.
- Hospital de Alta Complegidad El Cruce, Florencio Varela, Argentina.
- Hospital Cesar Milstein, Universidad de Buenos Aires, Ciudad de Bs AS, Argentina.
Zitieren
APA
Garcia-Salinas, R., Sommerfleck, F., Benitez, A., Dellepiane, A., Estevez, A., Fenucci, M., & Gomez, G. (2026). High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina. Rheumatology International. https://doi.org/10.1007/s00296-026-06131-2
Vancouver
Garcia-Salinas R, Sommerfleck F, Benitez A, Dellepiane A, Estevez A, Fenucci M, et al. High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina. Rheumatology International. 2026. doi:10.1007/s00296-026-06131-2
BibTeX
@article{GarciaSalinas2026,
author = {Garcia-Salinas, Rodrigo and Sommerfleck, Fernando and Benitez, Alejandro and Dellepiane, Analia and Estevez, Adrian and Fenucci, Maximiliano and Gomez, Gimena},
title = {High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina},
journal = {Rheumatology International},
year = {2026},
doi = {10.1007/s00296-026-06131-2}
}
EUVIMED